BioVie: Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s

 Data from Phase 2a trial in Parkinson’s Disease suggest patients treated with NE3107 experienced significant improvements in non-motor symptoms and motor control while placebo-treated patients worsened

Data from Phase 3 trial in mild to moderate Alzheimer’s Disease suggest NE3107 may have the potential to realign physiological processes in patients consistent with decreased neurocognitive decline and diseases of aging

The presentation Improvement of Non-Motor Symptoms with NE3107 Adjunctive to Carbidopa/Levodopa in Patients with Parkinson’s Disease: A Phase 2A, Placebo-Controlled Study will be presented at 15:10 GMT on March 9, 2024 

https://www.globenewswire.com/news-release/2024/03/01/2838786/0/en/BioVie-s-NE3107-Demonstrates-Potential-Improvements-in-Motor-and-Non-motor-Symptoms-for-Parkinson-s-Disease-Patients-and-May-Be-Realigning-Physiological-Processes-for-Alzheimer-s-P.html